X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (647) 647
index medicus (633) 633
female (493) 493
hematology (485) 485
male (483) 483
transplantation (439) 439
adult (415) 415
middle aged (411) 411
myeloablative agonists - therapeutic use (334) 334
immunology (314) 314
transplantation conditioning - methods (290) 290
adolescent (274) 274
transplantation, homologous (261) 261
myeloablative agonists - adverse effects (259) 259
bone-marrow-transplantation (246) 246
aged (237) 237
hematopoietic stem cells (233) 233
oncology (230) 230
myeloablative agonists - administration & dosage (227) 227
stem cells (217) 217
hematopoietic stem cell transplantation - adverse effects (214) 214
hematology, oncology and palliative medicine (194) 194
treatment outcome (194) 194
retrospective studies (193) 193
hematopoietic stem cell transplantation (181) 181
child (171) 171
transplantation conditioning - adverse effects (164) 164
survival analysis (160) 160
versus-host-disease (144) 144
young adult (142) 142
stem-cell transplantation (136) 136
vidarabine - analogs & derivatives (136) 136
hematopoietic stem cell transplantation - methods (135) 135
child, preschool (134) 134
transplantation conditioning (133) 133
graft vs host disease - prevention & control (123) 123
chemotherapy (113) 113
disease-free survival (108) 108
hematologic neoplasms - therapy (108) 108
risk factors (106) 106
care and treatment (102) 102
busulfan - administration & dosage (100) 100
health aspects (100) 100
recurrence (99) 99
infant (96) 96
graft vs host disease - etiology (95) 95
graft vs host disease - mortality (94) 94
analysis (93) 93
cyclophosphamide (93) 93
leukemia (93) 93
cancer (92) 92
transplantation, autologous (92) 92
busulfan (89) 89
mortality (89) 89
bone marrow (85) 85
article (84) 84
busulfan - adverse effects (80) 80
unrelated donors (79) 79
stem cell transplantation (77) 77
therapy (77) 77
graft vs host disease - immunology (76) 76
vidarabine - administration & dosage (76) 76
follow-up studies (75) 75
melphalan - administration & dosage (73) 73
fludarabine (72) 72
acute myeloid-leukemia (71) 71
prospective studies (69) 69
survival rate (69) 69
acute disease (68) 68
time factors (68) 68
hematopoietic stem cell transplantation - mortality (66) 66
prognosis (66) 66
children (65) 65
hematologic neoplasms - mortality (65) 65
dosage and administration (64) 64
leukemia, myeloid, acute - therapy (63) 63
research (63) 63
immunosuppressive agents - therapeutic use (62) 62
graft vs host disease - pathology (61) 61
cyclophosphamide - administration & dosage (59) 59
vidarabine - therapeutic use (58) 58
total-body irradiation (57) 57
hematologic neoplasms - immunology (56) 56
patient outcomes (56) 56
risk (56) 56
busulfan - therapeutic use (55) 55
melphalan - adverse effects (55) 55
multiple myeloma - therapy (55) 55
melphalan (54) 54
cyclophosphamide - therapeutic use (51) 51
multiple myeloma (51) 51
survival (50) 50
antineoplastic combined chemotherapy protocols - therapeutic use (49) 49
combined modality therapy (48) 48
cyclophosphamide - adverse effects (47) 47
incidence (47) 47
pediatrics (47) 47
whole-body irradiation (47) 47
hematologic malignancies (45) 45
hematologic neoplasms - pathology (45) 45
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (650) 650
French (4) 4
Spanish (2) 2
Chinese (1) 1
Danish (1) 1
Hungarian (1) 1
Italian (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2013, Volume 19, Issue 1, pp. 117 - 122
Abstract Fifty patients with high-risk hematologic malignancies, underwent an unmanipulated haploidentical bone marrow transplantation (BMT), followed by... 
Hematology, Oncology and Palliative Medicine | Haploidentical transplantations | Acute leukemia | HLA | Posttransplantation cyclophosphamide | Allogeneic stem cell transplant | MORTALITY | IMMUNOLOGY | RECIPIENTS | VERSUS-HOST-DISEASE | TRANSPLANTATION | REDUCED-INTENSITY | ACUTE-LEUKEMIA | HIGH-RISK | HAPLOTYPE | OUTCOMES | STEM-CELL TRANSPLANTATION | HEMATOLOGY | BLOOD | Hematologic Neoplasms - therapy | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Follow-Up Studies | Myeloablative Agonists - adverse effects | Thiotepa - administration & dosage | Hematologic Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Busulfan - administration & dosage | Cyclophosphamide - adverse effects | Transplantation, Homologous | Graft vs Host Disease - mortality | Antineoplastic Agents - adverse effects | Bone Marrow Transplantation | Adult | Female | Retrospective Studies | Graft vs Host Disease - etiology | Immunosuppressive Agents - administration & dosage | Acute Disease | Busulfan - adverse effects | Vidarabine - adverse effects | Survival Rate | Vidarabine - analogs & derivatives | Disease-Free Survival | Adolescent | Myeloablative Agonists - administration & dosage | Graft vs Host Disease - prevention & control | Immunosuppressive Agents - adverse effects | Aged | Vidarabine - administration & dosage | Transplantation Conditioning | Chronic Disease | Thiotepa - adverse effects | Antimitotic agents | Pneumonia | Cyclophosphamide | Bacterial pneumonia | Mortality | Bone marrow | Transplantation | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 06/2008, Volume 111, Issue 12, pp. 5530 - 5536
Journal Article
by Boelens, Jaap Jan and Boelens, Jaap Jan and Aldenhoven, Mieke and Aldenhoven, Mieke and Purtill, Duncan and Purtill, Duncan and Ruggeri, Annalisa and Ruggeri, Annalisa and Defor, Todd and DeFor, Todd and Wynn, Robert and Wynn, Robert and Wraith, E and Wraith, Ed and Cavazzana-Calvo, Marina and Cavazzana-Calvo, Marina and Rovelli, Attilio and Rovelli, Attilio and Fischer, Alain and Fischer, Alain and Tolar, Jakub and Tolar, Jakub and Prasad, Vinod K and Prasad, Vinod K and Escolar, Maria and Escolar, Maria and Gluckman, Eliane and Gluckman, Eliane and O'Meara, Anne and O’Meara, Anne and Orchard, Paul J and Orchard, Paul J and Veys, Paul and Veys, Paul and Eapen, Mary and Eapen, Mary and Kurtzberg, Joanne and Kurtzberg, Joanne and Rocha, Vanderson and Rocha, Vanderson and Eurocord, Eurocord and Malech, H and Horwitz, E and Inborn Errors Working Party of European Blood and Marrow Transplant group, Errors Working Party of European Blood and Marrow Transplant group and Le-Rademacher, J and Duke University Blood and Marrow Transplantation Program, University Blood and Marrow Transplantation Program and He, W and Centre for International Blood and Marrow Research, for International Blood and Marrow Research and Gaspar, B and Porta, F and Driscoll, T.A and Landi, D.B and Martin, P.L and Page, K.M and Parikh, H and Ctr Int Blood Marrow Res and Duke Univ and Inborn Errors Working Party of European Blood and Marrow Transplant group and Duke University Blood and Marrow Transplantation Program and Eurocord and Centre for International Blood and Marrow Research and on behalf of all participating centers from Eurocord, Inborn Errors Working Party of European Blood and Marrow Transplant group, Duke University, and the Centre for International Blood and Marrow Research
Blood, ISSN 0006-4971, 05/2013, Volume 121, Issue 19, pp. 3981 - 3987
Journal Article
Nature Neuroscience, ISSN 1097-6256, 09/2011, Volume 14, Issue 9, pp. 1142 - 1149
In multiple sclerosis and the experimental autoimmune encephalitis (EAE) mouse model, two pools of morphologically indistinguishable phagocytic cells,... 
EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | MULTIPLE-SCLEROSIS | BONE-MARROW-TRANSPLANTATION | DEMYELINATING DISEASE | EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS | SPINAL-CORD | CENTRAL-NERVOUS-SYSTEM | CNS MICROGLIA | BLOOD-BRAIN-BARRIER | NEUROSCIENCES | PERIVASCULAR CELLS | Myeloablative Agonists - adverse effects | Receptors, Interleukin-8A - genetics | Encephalomyelitis, Autoimmune, Experimental - etiology | Green Fluorescent Proteins - genetics | Bone Marrow Transplantation - methods | Parabiosis - methods | Whole-Body Irradiation - adverse effects | Chemotaxis, Leukocyte - physiology | Flow Cytometry | Microglia - physiology | Time Factors | Female | Microfilament Proteins - metabolism | Bromodeoxyuridine - metabolism | Monocytes - physiology | Disease Models, Animal | Calcium-Binding Proteins - metabolism | Macrophages - physiology | Severity of Illness Index | Encephalomyelitis, Autoimmune, Experimental - surgery | Encephalomyelitis, Autoimmune, Experimental - pathology | Mice, Inbred C57BL | Mice, Transgenic | Disease Progression | Inflammation - therapy | Animals | Encephalomyelitis, Autoimmune, Experimental - prevention & control | Mice | CD11b Antigen - metabolism | Receptors, CCR2 - deficiency | Physiological aspects | Development and progression | Multiple sclerosis | Research | Diagnosis | Macrophages | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 6, pp. 701 - 709
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 11/2017, Volume 66, Issue 11, pp. 1425 - 1436
The primary aim of this clinical trial was to determine the feasibility of delivering first-generation CAR T cell therapy to patients with advanced, CEACAM5+... 
Persistence | Immunology | Medicine & Public Health | Chimeric antigen receptor | Toxicity | Oncology | Cancer Research | T cells | CEA | TARGET | CHIMERIC IMMUNE RECEPTORS | METASTASES | IMMUNOLOGY | CANCER | TRIAL | ONCOLOGY | IMMUNOTHERAPY | LYMPHOMA | GENE-THERAPY | PHASE-I | LYMPHOCYTES | Cyclophosphamide - administration & dosage | Myeloablative Agonists - adverse effects | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Carcinoembryonic Antigen - genetics | Drug Resistance, Neoplasm | Male | Interferon-gamma - metabolism | Myeloablative Agonists - agonists | Cyclophosphamide - adverse effects | T-Lymphocytes - transplantation | Carcinoembryonic Antigen - metabolism | Neoplasms - therapy | Neoplasms - genetics | T-Lymphocytes - metabolism | Adult | Female | Receptors, Antigen, T-Cell - immunology | Lung - metabolism | Interleukin-6 - metabolism | Anemia - etiology | Immunotherapy, Adoptive - adverse effects | Immunotherapy, Adoptive - methods | Abdominal Pain - etiology | GPI-Linked Proteins - immunology | Receptors, Antigen, T-Cell - metabolism | Carcinoembryonic Antigen - immunology | Vidarabine - adverse effects | Treatment Outcome | Vidarabine - analogs & derivatives | GPI-Linked Proteins - metabolism | Neoplasms - immunology | Interferon-gamma - immunology | Interleukin-6 - immunology | Vomiting - etiology | T-Lymphocytes - immunology | Aged | Receptors, Antigen, T-Cell - genetics | Vidarabine - administration & dosage | Cohort Studies | GPI-Linked Proteins - genetics | CEA (Oncology) | Cells | Cytokines | Control methods | Lung | Feasibility studies | Lymphocytes T | Malignancy | Epithelium | Patients | Interleukin 6 | Infusion | Carcinoembryonic antigen | Cyclophosphamide | Elevated | Cell activation | Fludarabine | Interleukin 2 | Lymphocytes | Production methods | γ-Interferon | Biocompatibility | Preconditioning | Index Medicus | Original
Journal Article
Blood, ISSN 0006-4971, 03/2016, Volume 127, Issue 11, pp. 1502 - 1508
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 20, pp. 4256 - 4262
Journal Article
Cancer, ISSN 0008-543X, 11/2013, Volume 119, Issue 21, pp. 3805 - 3811
BACKGROUNDThe combination of fludarabine, cyclophosphamide, and rituximab (FCR) has produced improved response rates and a prolonged survival in patients with... 
chronic lymphocytic leukemia | combination of fludarabine, cyclophosphamide, and rituximab | cytopenia | prognosis | and rituximab | CHEMOIMMUNOTHERAPY | combination of fludarabine | REGIMEN | ACUTE MYELOID-LEUKEMIA | MYELODYSPLASTIC SYNDROME | TRIAL | MAINTENANCE | ONCOLOGY | INITIAL THERAPY | cyclophosphamide | COMBINATION CHEMOTHERAPY | PROGRESSION-FREE | LYMPHOMA | Myeloablative Agonists - therapeutic use | Cyclophosphamide - administration & dosage | Immunotherapy - methods | Myeloablative Agonists - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Young Adult | Aged, 80 and over | Clinical Trials, Phase II as Topic - statistics & numerical data | Adult | Female | Leukemia, Lymphocytic, Chronic, B-Cell - blood | Retrospective Studies | Leukemia, Lymphocytic, Chronic, B-Cell - immunology | Immune Tolerance - drug effects | Pancytopenia - chemically induced | Vidarabine - adverse effects | Pancytopenia - diagnosis | Rituximab | Treatment Outcome | Vidarabine - analogs & derivatives | Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology | Immunotherapy - adverse effects | Leukemia, Lymphocytic, Chronic, B-Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Pancytopenia - epidemiology | Adolescent | Aged | Vidarabine - administration & dosage | Pancytopenia - blood | Antibodies, Monoclonal, Murine-Derived - adverse effects | Chronic lymphocytic leukemia | Cyclophosphamide | Fludarabine | Dosage and administration | Research | Drug therapy, Combination | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2008, Volume 26, Issue 9, pp. 1519 - 1525
PURPOSE: The Prospective Oral Mucositis Audit assessed the incidence, duration, and determinants of severe oral mucositis (OM; WHO oral toxicity scale grades 3... 
TRIAL | MULTICENTER | RISK-FACTORS | PALIFERMIN | ONCOLOGY | CONSEQUENCES | ECONOMIC OUTCOMES | COMPLICATIONS | STEM-CELL TRANSPLANTATION | RECIPIENTS | CANCER-THERAPY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Myeloablative Agonists - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Medical Audit | Male | Transplantation, Autologous | Lymphoma, Non-Hodgkin - surgery | Cytarabine - adverse effects | Incidence | Dose-Response Relationship, Drug | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Bone Marrow Transplantation | Adult | Female | Stomatitis - epidemiology | Transplantation Conditioning - adverse effects | Transplantation Conditioning - methods | Multiple Myeloma - surgery | Carmustine - adverse effects | Lymphoma, Non-Hodgkin - drug therapy | Etoposide - adverse effects | Risk Assessment | Risk Factors | Europe - epidemiology | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Cytarabine - administration & dosage | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, Non-Hodgkin - therapy | Stomatitis - chemically induced | Myeloablative Agonists - administration & dosage | Aged | Research Design | Carmustine - administration & dosage | Index Medicus
Journal Article